Civil society organisations, patient groups and health activists have been concerned about intellectual property provisions being discussed in RCEP which undermine access to medicines and affordable treatment for patients
In many countries, the implementation of the TRIPS-plus measures has significantly increased the cost of medicines.
Canada’s negotiators extended data protection on biologics without knowing impact on prices.
Patients may need to wait an extra five or 10 years to access generic medicines, which could raise healthcare costs by as $100 billion over the next five years, according to the latest CPhI annual report
Experts are fuming, saying USMCA will hamper Canada’s innovation economy and hike costs to the health care system over patented drugs.
The United States has throughout history been the principal demandeur of maximalist intellectual property, backed by a powerful pharmaceutical lobby.
The 10-year span is more than what had existed before but the biopharma industry has long argued for the same 12-year exclusivity that exists for biologics within the US market.
While some states in East and Southeast Asia favor the 16-nation RCEP trade deal, many civil society groups say it lacks transparency and public participation.
A leaked draft of the negotiating text has revealed some proposed harmful intellectual property provisions that could undermine access to price-lowering, generic medicines, and thus, life-saving treatment to millions of people.
Dr Othoman Mellouk is a Moroccan treatment advocate who has been working on intellectual property and access to medicines for more than a decade.
Trade Minister Steven Ciobo has promised to take a hard line with Europe on the question of cheap medicines and his counterpart Cecilia Malmström foresees “difficult” negotiations over Australian producers using European names such as "parmesan".
Government should reject Trump’s threat to affordable medicines through TPP and other trade deals.
Ukrainian lawmakers are poised to approve sweeping patent reform legislation, driven in large part by a push by patients’ groups for better access to affordable medicines and healthcare.
Extended patent protections under Canada’s free trade deal with the European Union could cost the federal government some $270 million a year, according to a new report by the Parliamentary Budget Officer.
A wide-ranging list of international nongovernmental organisations issued a letter to European Trade Commissioner Cecilia Malmström opposing a proposal to establish a “watch list” of countries deemed failing to protect European intellectual property.
The US trade barriers list shows that Liam Fox could let more than just chlorinated chicken into the UK. The public deserve to know the details
Officials from the European Union (EU) and India are expected to meet in Brussels on April 12th to resume technical talks on the long-stalled EU-India free trade agreement (FTA). A leaked draft of the agreement, which has been under discussion since 2007, contains proposals from the EU that push for intellectual property (IP) provisions in the FTA that could jeopardize access to affordable medicines.
NAFTA was the first “trade” agreement that included new monopoly powers for Big Pharma companies.
US-led multilateral trade agreements have forced poorer foreign countries to honor patents in exchange for the benefits of bringing multi-national corporations—and their factory jobs—abroad.
Japan’s role in RCEP negotiations appears to have been shaped by its participation in the TPP. Japan is now championing for expanded intellectual property right provisions which may block access to affordable medicines